Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis

JT Miura; HM Kroon; GM Beasley; D Mullen; NE Farrow; PJ Mosca; MC Lowe; CR Farley; Y Kim; SMH Naqvi; A Potdar; H Daou; J Sun; JM Farma; MA Henderson; D Speakman; J Serpell; KA Delman; B Mark Smithers; BJ Coventry; DS Tyler; JF Thompson; JS Zager

Journal article

Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis

JT Miura, HM Kroon, GM Beasley, D Mullen, NE Farrow, PJ Mosca, MC Lowe, CR Farley, Y Kim, SMH Naqvi, A Potdar, H Daou, J Sun, JM Farma, MA Henderson, D Speakman, J Serpell, KA Delman, B Mark Smithers, BJ Coventry Show all

Annals of Surgical Oncology | SPRINGER | Published : 2019

DOI: 10.1245/s10434-019-07288-w

Abstract

Background: Isolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose regional chemotherapy to patients with locally advanced or in-transit melanoma located on a limb. The current international multicenter study evaluated the perioperative and long-term oncologic outcomes for patients who underwent ILI for stage 3B or 3C melanoma. Methods: Patients undergoing a first-time ILI for stage 3B or 3C melanoma (American Joint Committee on Cancer [AJCC] 7th ed) between 1992 and 2018 at five Australian and four United States of America (USA) tertiary referral centers were identified. The primary outcome measures included treatment response, in-field (IPFS) and distant pr..

View full abstract